Quickstart Highlights

LL-37 (also known as CAP-18) is a 37-amino-acid cationic antimicrobial peptide derived from the C-terminal of human cathelicidin (hCAP18)^[1]. It is the only known human cathelicidin, exhibiting broad-spectrum antibacterial activity and immune-modulating properties^[2][3]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
• Typical daily range: 100–400 µg once daily (gradual titration).
• Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 µg on a U-100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 4 weeks; avoid freeze–thaw cycles.

Protocol Overview

Concise summary of the once-daily regimen.

• Goal: Support antimicrobial defense and wound-healing processes^[4][5].
• Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
• Dose Range: 50–400 µg daily with gradual titration.
• Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

• Start: 50–100 µg daily; increase by ~50 µg each week as tolerated.
• Target: 200–400 µg daily by Weeks 4–8.
• Frequency: Once per day (subcutaneous); optional 5-on/2-off schedule.
• Cycle Length: 8–12 weeks; optional extension to 16 weeks.
• Timing: Any consistent time; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality^[6][7].

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable ~24 months.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) for up to 4 weeks; frozen at −20 °C (−4 °F) for up to 6 months.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container^[8].
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation^[9].
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• Early-phase doses (≤10 units) benefit from 30- or 50-unit syringes for precision.

How This Works

LL-37 exerts both direct and indirect antimicrobial effects. Its amphipathic, cationic α-helical structure (net +6 charge) allows it to preferentially bind and disrupt negatively charged microbial membranes^[2]. Beyond direct killing, LL-37 modulates host immunity: in murine sepsis models, it induced neutrophils to release microvesicles rich in antimicrobial proteins, lowering bacterial burden and improving survival^[3]. LL-37 can also bind bacterial lipopolysaccharide (LPS) and block its interaction with CD14/TLR4, reducing endotoxin-triggered TNF release and neutrophil apoptosis^[2]. These combined mechanisms help explain its potential in infection control and tissue-repair contexts.

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

• In chronic venous leg ulcers (which often lack endogenous LL-37), topical treatment with synthetic LL-37 significantly accelerated healing rates compared to placebo^[4].
• In diabetic foot ulcer trials, LL-37 cream improved granulation tissue formation and wound closure^[5].
• Broad-spectrum antimicrobial action helps clear infections; in experimental sepsis models, LL-37 treatment reduced bacterial loads and mortality^[3].
• Generally well tolerated; occasional mild injection-site reactions (redness, itch) may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

• Optimize vitamin D status, as vitamin D upregulates endogenous cathelicidin/LL-37 expression^[10].
• Support wound healing with adequate protein intake and micronutrient sufficiency (zinc, vitamin C).
• Maintain proper wound hygiene and dressing protocols if using for tissue-repair goals.
• Prioritize sleep and stress management to support immune function and recovery.

Injection Technique

General subcutaneous guidance from clinical best-practice resources^[11].

• Clean the vial stopper and skin with alcohol; allow to dry.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[9][12].
• Do not aspirate for subcutaneous injections; inject slowly and steadily^[12].
• Rotate sites systematically (abdomen, thighs, upper arms) and move at least 2–3 cm from the previous site^[9].
• Use aseptic technique; always use a new sterile needle and syringe for each injection^[8].

Recommended Source

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

Shop at Amino Labs

References